#NationalDNADay honors the Human Genome Project's completion in 2003 and DNA's double helix discovery in 1953. These milestones laid Tome's foundation and inspired our mission of curing patients through cell and integrative gene therapies.

#DNA #genomeediting

On this episode of BioProcess Online’s Business of Biotech with @MattPillar, Tome President & CEO Dr. Rahul Kakkar talks about how his medical background shaped his role in #biotech and his excitement for the work Tome is doing to improve patients’ lives.

bit.ly/3JtwSNO

We are thrilled to share that members of the Tome team will present their abstracts at the 2024 ASGCT Annual Meeting on 5/9. We are proud of our team's accomplishments in cell and gene therapy and look forward to their presentations!

bit.ly/3IkVuHV

#ASGCT24

Gene editing is no longer science fiction. It's science fact.

In this article by The Wall Street Journal, learn about the stories behind people who have received gene editing treatments and how this transformative technology is changing their lives.

#GeneEditing

on.wsj.com/4a4YKDw

Programmable genomic integration (PGI) is key to everything we do at Tome.

PGI is the ability to insert any genetic sequence with site-specific precision in the genome.

bit.ly/3vydOuA

#GeneEditing

The Tome team is hitting the court for the 2024 Special Olympics Summer Games Bio-Ball tournament!

Please consider donating to Tome’s team to support Special Olympics MA mission of fostering inclusion, fun, community, and comradery.

bit.ly/3W2jFCW

We're honored to be on Boston Business Journal's list of Top 20 Best Places to Work in the medium-sized company category! A huge THANK YOU to all of our Tome-mates for making Tome such a great place to work. bizjournals.com/boston/news/20…

We are proud to announce the issuance of US Patent 11,952,571 for “Systems, Methods, and Compositions for Site-Specific Genetic Engineering Using Programmable Addition via Site-Specific Targeting Elements (PASTE)” by the @USPTO.

Read more here: bit.ly/3IkVuHV

We love hands-on science education!

Shout out to science educators using CRISPR in a Box kits to make #CRISPR approachable and understandable.

Knowledge is power, and these educators are empowering the future generation of genetic engineers!

yhoo.it/3INSxjy

#STEM

Curious about #CRISPR technology?

CRISPR-based systems are moving lightning-fast, but this review from Nature Reviews Molecular Cell Biology can bring you up to speed.

Explore technological advancements, strengths and weaknesses, and the potential impact on human health.

go.nature.com/430sheV

Tome's President & CEO, Dr. Rahul Kakkar, spoke with Don Davis on the Life Science Success podcast about his experience founding #biotech companies while balancing a medical practice and his vision for Tome's future in #genomicmedicine .

bit.ly/48UMFzC

It’s #CelebrateScientistsDay , and today, we recognize the brilliant minds who have dedicated their lives to science. From groundbreaking discoveries to new technological advancements, thank you to all the scientists who have made our world a better place!

How can we ensure CRISPR-based cures can reach patients with the rarest of rare diseases?

We applaud the plan by Innovative Genomics Institute to tackle diseases untouched to date by biopharma companies.

Learn about their approach in this article from STAT:

statnews.com/2024/01/09/dou…

#CRISPR

Tome is proud to announce the formation of its Science and Technology Advisory Committee (STAC) made up of four instrumental leaders in the delivery, development, and manufacturing of genomic medicines.

Learn more here: bit.ly/3IkVuHV

Happy #EmployeeAppreciationDay !

As a small token of appreciation, we hosted a breakfast for our employees to honor their commitment and hard work.

With their insightful ideas and unwavering commitment, our team is the driving force behind our success.

#RareDiseaseDay is a time of unity and support for individuals & families living with rare diseases.

With the help of technology, like PGI, we can impact the rare disease community. Let's all work together to improve the lives of those affected.

#RareDiseases #GeneEditing

Tome’s CEO, Rahul Kakkar, sat down with Theral Timpson of mendelspod to discuss how genomic-based therapies are crucial in curing diseases versus treating them.

bit.ly/42HeUjC

#CRISPR #genomeediting #TomeBio #genomicmedicine

Happy #InternationalDayOfWomenAndGirlsInScience !

Women profoundly impact research and innovation and are invaluable as we pursue cures for a lifetime. Today, we’re highlighting a few of our very own who are paving the way for a more inclusive and diverse future.

#WomenInSTEM

The FDA recently approved Casgevy, a CRISPR therapeutic for beta-thalassemia. Congrats to Vertex Pharmaceuticals and CRISPR Therapeutics on this important milestone in genomic editing treatments.

bit.ly/499gEUO

#CRISPR

We are excited to welcome Daniel Curran, MD, to Tome’s Board of Directors and look forward to the valuable corporate and drug development expertise he will bring to Tome.

bit.ly/3HEJ0L2

#TomeBio #CellandGeneTherapy